As per statistics, there are over 180 bispecific antibodies in clinical trials and nearly 260 in pre-clinical development around the world. Among them, CD3 is considered to be the primary target.

To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the ...

targeting a range of cancers with different bispecific antibody designs, linkers, and payloads. For instance, BL-B01D1 ...

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS. “We discovered petosemtamab from an unbiased ...

Petosemtamab is a bispecific antibody targeting EGFR and LGR5, intended to improve treatment outcomes for patients who have not responded to previous therapies. The trial will focus on evaluating ...

By selecting degrader receptors enriched in disease tissue, EpiBiologics reports that its EGFR-targeting bispecific EpiTAC antibody drives synergistic anti-tumor activity in vivo while preserving ...

Petosemtamab is a Biclonics ® targeting EGFR and LGR5 ... discovered petosemtamab from an unbiased screen of over 500 bispecific antibodies tested for the ability to inhibit cancer-derived ...